Stock Yards Bank & Trust’s Galectin Therapeutics GALT Stock Holding History

Stock Yards Bank & Trust’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$48.7K	Hold	10,500	–	–	﹤0.01%	397
2026 Q1	$29.3K	Hold	10,500	–	–	﹤0.01%	396
2025 Q4	$43.7K	Hold	10,500	–	–	﹤0.01%	397
2025 Q3	$44.5K	Hold	10,500	–	–	﹤0.01%	389
2025 Q2	$22.2K	Hold	10,500	–	–	﹤0.01%	381
2025 Q1	$12.8K	Hold	10,500	–	–	﹤0.01%	379
2024 Q4	$13.5K	Hold	10,500	–	–	﹤0.01%	365
2024 Q3	$28.9K	Hold	10,500	–	–	﹤0.01%	373
2024 Q2	$23.7K	Hold	10,500	–	–	﹤0.01%	376
2024 Q1	$25.1K	Hold	10,500	–	–	﹤0.01%	391
2023 Q4	$17.4K	Hold	10,500	–	–	﹤0.01%	377
2023 Q3	$20.2K	Hold	10,500	–	–	﹤0.01%	383
2023 Q2	$15.1K	Hold	10,500	–	–	﹤0.01%	393
2023 Q1	$22K	Hold	10,500	–	–	﹤0.01%	404
2022 Q4	$12K	Hold	10,500	–	–	﹤0.01%	411
2022 Q3	$17K	Hold	10,500	–	–	﹤0.01%	405
2022 Q2	$14K	Hold	10,500	–	–	﹤0.01%	414
2022 Q1	$17K	Buy	+10,500	New	+$20.3K	﹤0.01%	269

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Stock Yards Bank & Trust's GALT Position: Q2 2026 in Review

Stock Yards Bank & Trust held its Galectin Therapeutics (GALT) position steady in Q2 2026 at 10,500 shares worth $48.7K. The position accounts for ﹤0.01% of the portfolio, ranked #397.

Stock Yards Bank & Trust first reported a position in GALT in Q1 2022 and has held it in 18 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

Stock Yards Bank & Trust held 10,500 shares of Galectin Therapeutics worth $48.7K as of Q2 2026.
Stock Yards Bank & Trust left its Galectin Therapeutics share count unchanged in Q2 2026.
Galectin Therapeutics made up ﹤0.01% of Stock Yards Bank & Trust's portfolio in Q2 2026, its #397 holding.
Stock Yards Bank & Trust first reported a position in Galectin Therapeutics in Q1 2022 and has held it in 18 quarters since.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Stock Yards Bank & Trust's 13F filing for Q2 2026, filed 13 Aug 2026.